CANbridge Pharmaceuticals (SEHK:1228) Profit Swing To C¥59.2m Tests Bullish Narratives

CANbridge Pharmaceuticals (SEHK:1228) opened FY 2025 with first half revenue of C¥22.2 million and basic EPS of C¥0.14, while trailing twelve month figures show revenue of C¥50.0 million and basic EPS of C¥0.03 as the company moved into positive net income territory. Over recent reporting periods, revenue has shifted from C¥44.8 million in 1H 2024 to C¥40.3 million in 2H 2024 and then to C¥22.2 million in 1H 2025, alongside a swing in net income from a loss of C¥247.3 million in 1H 2024 to a profit of C¥59.2 million in 1H 2025. This may prompt investors to focus closely on how resilient those margins prove to be.

See our full analysis for CANbridge Pharmaceuticals.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the most widely held narratives around CANbridge and where those stories might be tested by the data.

Curious how numbers become stories that shape markets? Explore Community Narratives

Profit swings from C¥247.3m loss to C¥59.2m profit

• Net income moved from a loss of C¥247.3 million in 1H 2024 to a profit of C¥59.2 million in 1H 2025, while total revenue over those halves went from C¥44.8 million to C¥22.2 million.
• What stands out for a bullish narrative is that earnings turned positive even as revenue in the latest half sits below the C¥44.8 million and C¥40.3 million levels seen in 1H and 2H 2024. This heavily supports the view that earnings quality is high but also raises the question of how dependent this result is on cost or mix changes rather than top line strength.
  • Trailing twelve month net income of C¥14.8 million, compared with losses of C¥136.1 million and C¥442.6 million in the prior trailing snapshots, is consistent with the 35.2% annualised earnings growth figure cited over five years and underpins the reward side of the story.
  • At the same time, trailing twelve month revenue of C¥50.0 million is below the C¥62.6 million and C¥85.1 million in earlier trailing periods, which challenges a simple bullish claim that profit progress is currently paired with expanding sales.

P/E of 96.4x versus 38x sector

• The shares trade on a trailing P/E of 96.4x, compared with 1.8x for peers and 38x for the wider Asian biotechs group, at a share price of HK$2.73.
• Critics highlight that such a premium multiple sits awkwardly next to balance sheet pressure and past dilution, which supports a bearish narrative focused on financial risk rather than just on the income statement.
  • Negative shareholders’ equity and debt that is not well covered by operating cash flow are clear stress points that line up with concerns about how future investment or setbacks might be funded.
  • Substantial shareholder dilution in the past year means existing holders have already absorbed ownership pressure, which fits with bears’ view that further capital raising is a key risk if conditions tighten again.

High earnings quality but volatile share price

• Trailing twelve month earnings are assessed as high quality and the company has become profitable over the last year, yet the share price has been more volatile than the Hong Kong market in the last three months.
• What is interesting for a general market view is that this combination of improving profitability and high reported earnings quality sits alongside above market volatility. This suggests investors are still weighing the balance between the recent profit track record and the financial risks on the balance sheet.
  • The move from trailing twelve month losses of C¥442.6 million and C¥136.1 million to a profit of C¥14.8 million is a clear shift in the income statement, but volatility indicates that price moves are not tracking this change in a smooth way.
  • With a five year annualised earnings growth rate of 35.2% set against the current 96.4x P/E, some investors may see the earnings profile as attractive while others focus on how that volatility and negative equity feed into their risk tolerance.

If you want to see how other investors are framing this mix of high earnings quality, rich valuation, and balance sheet risk, it helps to read through the shared narratives and compare them with the raw numbers.Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on CANbridge Pharmaceuticals's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Given the mix of optimism and concern running through this update, it makes sense to review the figures yourself and decide how the story fits your portfolio risk comfort. You can then round out that view with 1 key reward and 4 important warning signs

Explore Alternatives

High share price volatility, a rich 96.4x P/E against sector peers, negative shareholders’ equity and recent dilution all highlight meaningful balance sheet and risk concerns.

If those red flags make you hesitant, take a few minutes to compare with companies in the 265 resilient stocks with low risk scores that score better on financial strength and risk control.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com